Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1070
Small font sizeDefault font sizeIncrease font size
Navigate here
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (1,239 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   Article Figures

 Article Access Statistics
    PDF Downloaded234    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


  Table of Contents  
Year : 2011  |  Volume : 48  |  Issue : 3  |  Page : 363-364

Preneoplastic and neoplastic megakaryocyte/platelet disorders: Three case reports

Department of Pathology, CSMMU, Lucknow, India

Date of Web Publication14-Sep-2011

Correspondence Address:
R Kushwaha
Department of Pathology, CSMMU, Lucknow
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.84913

Rights and Permissions

How to cite this article:
Kumar A, Kushwaha R, Singh U S. Preneoplastic and neoplastic megakaryocyte/platelet disorders: Three case reports. Indian J Cancer 2011;48:363-4

How to cite this URL:
Kumar A, Kushwaha R, Singh U S. Preneoplastic and neoplastic megakaryocyte/platelet disorders: Three case reports. Indian J Cancer [serial online] 2011 [cited 2021 Aug 5];48:363-4. Available from: https://www.indianjcancer.com/text.asp?2011/48/3/363/84913


Neoplastic and preneoplastic conditions affecting the megakaryocyte lineage are rare among myelodysplasia and chronic myeloproliferative disorders. The incidence of essential thrombocythemia (ET) is 0.6-2.5 per 1 lakh persons per year. [1] Most patients are in fifth and sixth decades, with no major sex predilection. However, a second peak occurs in the third decade. [2]

Among the myelodysplastic syndrome (MDS), exact incidence of isolated deletion (5q) is still unknown. Acute megakaryoblastic leukemia (AML M7) accounts for <5% of all the cases of AML. [2] We herewith discuss case reports of these rare entities.

A 32-year female patient presented with pain in right hypogastrium, weakness, and digital ischemia. Peripheral blood showed normocytic normochromic RBC's, a WBC count of 46,200 cells/cu. mm, and a platelet count of 15.2 lakh cells/cu. mm [Figure 1]a. Bone marrow was hypercellular, erythropoiesis normoblastic, granulocytic precursors increased with normal maturation without dysplasia [Figure 1]b and c. Megakaryocytes showed hyperplasia. Large aggregates of megakaryocytes were present showing active platelet synthesis. Micromegakaryocytes were present in large number. Diagnosis of ET was made.
Figure 1: (a) Peripheral blood smear showing large platelet clumps and variable-sized platelets (leishman stain, ×10). (b) Bone marrow aspirate showing multilobated dysmorphic megakaryocytes (leishman stain, ×40). (c) Trephine biopsy showing clusters of megakaryocytes with hyperlobated nuclei (hematoxylin and eosin, ×40)

Click here to view

A 52-year-old male patient presented with progressive weakness. Peripheral blood showed macrocytic RBC's, thrombocythemia [Figure 2]a. Bone marrow was hypercellular with erythroid hypoplasia, megakaryocytes increased and small in size with hypolobated nuclei [Figure 2]b and c. There was no dysplasia in erythroid and myeloid lineages. A presumptive diagnosis of MDS with suspicion of isolated deletion (5q) was made. Cytogenetics showed deletion of 5q.

A 12-year boy presented with progressive weakness. Bone marrow was hypercellular with 30% blasts, and most of them were megakaryoblasts. These cells were of a large size with indented nucleus and cytoplasmic blebs [Figure 3]. Acute megakaryoblastic leukemia was diagnosed. These cells were positive for CD41 and CD61.
Figure 2: (a) Peripheral blood smear showing thrombocytosis (leishman stain, ×10). (b) Bone marrow aspirate showing hypolobated megakaryocytes (leishman stain, ×10). (c) Bone marrow aspirate showing monolobated megakaryocytes with emperipolesis (leishman stain, ×100)

Click here to view
Figure 3: Bone marrow aspirate showing megakaryoblasts with arrow pointing at cytoplasmic blebs (leishman stain, ×100)

Click here to view

ET is a chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage. Most cases occur in the fifth decade. However, it can be seen as early as in the third decade as seen in our case. Diagnosis requires a sustained platelet count of more than 450 × 10 9 /L in peripheral blood, increased number of large mature megakaryocytes in bone marrow, and clinically by episodes of thrombosis and hemorrhage. [2] The morphological findings in bone marrow biopsy are essential to distinguish ET from other myeloproliferative neoplasms, myeloid disorders, and reactive conditions that present with sustained thrombocytosis. The finding of even a mild degree of combined granulocytic and erythroid proliferation raises the possibility of polycythemia vera. However, it can be ruled out by the failure of iron replacement therapy to increase the hemoglobin to the level of the polycythemia vera range in the presence of decreased serum ferritin. [3]

The finding of granulocytic proliferation associated with bizarre, highly atypical megakaryocytes, makes it essential to distinguish ET from primary myelofibrosis. In primary myelofibrosis, there is bone marrow fibrosis, with peripheral blood leukoerythroblastosis, small to large megakaryocytes with an aberrant N:C ratio, hyperchromatic bulbous irregularly folded nuclei and clusters. MDS can be ruled out by the absence of dyserythropoiesis and dysgranulopoiesis. [4]

MDS with isolated deletion (5q) is a syndrome characterized by anemia with or without other cytopenias and/or thrombocytosis, in which the sole cytogenetic abnormality is del(5q). The megakaryocytic morphology is typically with monolobated nuclei. [5]

AML has a bimodal age distribution, with one peak in infancy and other in elderly. It represents 0.6-1.2% of cases of adult AML. Our case is unique as our patient is a 12-year-old male. [6]

  References Top

1.Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of ET in a well defined geographical area. Eur J Haematol 2000;65:132-9.  Back to cited text no. 1
2.Thiele J, Kbasnicka HM, Orazi A, Tesseri A, Gisslinger H. Essential thrombocythemia. In: Steven HS, editor. WHO classification of tumors of hematopoetic and lymphoid tissues. 4 th ed. Lyon, France: International agency for research on cancer; 2008. p. 48-50.  Back to cited text no. 2
3.James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK 2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;;434:1144-8.  Back to cited text no. 3
4.Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C. Clinical, morphological, cytogenetic and prognostic features of patients with myelodysplastic syndrome and del (5q) including band q31. Leukemia 2004;18:113-9.  Back to cited text no. 4
5.Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-9.  Back to cited text no. 5
6.Maria RB, John PG. Acute myeloid leukemia in adults. In: Greer, John P, editors. Wintrobes clinical hematology, 12 th ed, vol 2. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 1858.  Back to cited text no. 6


  [Figure 1], [Figure 2], [Figure 3]

This article has been cited by
1 A validated stability indicating LC method of assay and related substances for Finasteride
Srinivas, G. and Kishore Kumar, K. and Rama Koti Reddy, Y. and Mukkanti, K. and Kanumula, G.V. and Madhavan, P.
Journal of Chemical and Pharmaceutical Research. 2011; 3(6): 987-996


Print this article  Email this article


  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow